title: Validation and feasibility of a caloric expenditure measuring device in women with early-stage breast cancer.
abstract: OBJECTIVE
  The purpose of this study is to validate the Bodybugg (BB), a caloric expenditure measuring device, in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy for early-stage breast cancer.
  
  
  METHODS
  Twenty-five women with stages I-III breast cancer who were to receive adjuvant dose-dense doxorubicin/cyclophosphamide were recruited. Participants were asked to wear the BB and record activity logs for seven pretreatment days (prior to commencing chemotherapy) and seven posttreatment days (upon completing cycle 4 of chemotherapy). The BB's caloric expenditure measurements were used to calculate metabolic equivalent (MET) values of patients' recorded activities. BB-calculated METs were compared with matching METs from the 2011 Compendium of Physical Activities Tracking Guide to assess accuracy of the device.
  
  
  RESULTS
  The overall patient sample wore the device for an average of 5.32 (SD 1.75) pre- and 4.88 (SD 2.01) posttreatment days. The mean pairwise difference between BB and Compendium METs was 0.043 (SD 0.77) for 308 pretreatment activities recorded by 12 patients and 0.065 (SD 0.61) for 108 posttreatment activities recorded by 6 patients, indicating close to zero bias between the BB's and Compendium's measurements. Hierarchical linear modeling showed that Compendium METs strongly predict for BB METs (P < 0.00001).
  
  
  CONCLUSIONS
  The BB is feasible to use in study designs involving defined time periods of measurement and provides accurate and objective measurements of caloric expenditure in breast cancer patients.
authors.affiliation: Department of Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Waliany
authors.forename: Christina M
authors.initials: CM
authors.lastname: Dieli-Conwright
authors.forename: Paul H
authors.initials: PH
authors.lastname: Frankel
authors.forename: Arti
authors.initials: A
authors.lastname: Hurria
authors.forename: Joseph
authors.initials: J
authors.lastname: Chao
authors.forename: Brian
authors.initials: B
authors.lastname: Tiep
authors.forename: Joanne E
authors.initials: JE
authors.lastname: Mortimer
mesh_terms: D056044:Actigraphy / Q000295:instrumentation*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D002153:Calorimetry, Indirect / Q000295:instrumentation* / Q000379:methods; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004734:Energy Metabolism; D005221:Fatigue / Q000175:diagnosis / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000295:instrumentation*; D009043:Motor Activity; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide
references.citation: Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504
references.pmid: 10993420
references.citation: J Natl Cancer Inst. 2013 Dec 4;105(23):1821-32
references.pmid: 24151326
references.citation: Respir Med. 2009 Oct;103(10):1511-7
references.pmid: 19464863
references.citation: JPEN J Parenter Enteral Nutr. 2007 Nov-Dec;31(6):502-7
references.pmid: 17947607
references.citation: Cochrane Database Syst Rev. 2012 Nov 14;11:CD006145
references.pmid: 23152233
references.citation: Respir Med. 2011 Jun;105(6):922-9
references.pmid: 21276720
references.citation: J Clin Oncol. 2014 Apr 1;32(10):1040-9
references.pmid: 24470004
references.citation: Arch Phys Med Rehabil. 2010 Feb;91(2):261-7
references.pmid: 20159131
references.citation: Med Sci Sports Exerc. 2010 Nov;42(11):2134-40
references.pmid: 20386334
references.citation: J Natl Cancer Inst. 2004 Sep 1;96(17):1322-30
references.pmid: 15339970